Page 1

Glenmark Pharmaceuticals Limited Statement of unaudited financial results for the quarter ended 30 June , 2021 Particulars Quarter ended 30/06/2011 ( Unaudited ) Standalone Quarter ended 31/03/2021 ( Audited ) Refer note 4 I Revenue from operations ( a ) Net sales ( b ) Other operating income Total revenue from operations II Other income [ 1 ] e Glenmark A new way for a new world ( Rs.In Millions ) Quarter ended 30/06/2020 ( Unaudited ) Year ended 31/03/2021 ( Audited ) 21,292.40 128.77 21,421.17 18,231.51 272.18 18,503.69 16,524.45 304.77 16,829.22 74,509.11 1,170.22 75,679.33 1,382.08 1,168.58 1,348.49 3,962.37 Total income ( I +11 ) 22,803.25 19,672.27 18,177.71 79,641.70 IV Expenses : ( a ) Cost of materials consumed 8,459.53 6,458.51 5,917.41 26,782.60 ( b ) Purchases of stock - in - trade 1,401.60 840.33 762.73 3,159.55 ( c ) Changes in inventories of finished goods , work - in- progress and stock - in - trade 41.27 365,44 ( 157.24 ) 52.40 ( d ) Employee benefits expense 2,641.22 2,519.29 2,372.36 11,073.96 ( e ) Finance costs 590.15 625.07 599,38 2,658.98 ( 1 ) Depreciation , amortisation and impairment expense 374.42 370.00 358.09 1,508.15 ( g ) Other expenses 3,311.07 4,760.03 2,846.52 15,707.41 Total expenses ( IV ) 16,819.26 15,938.67 12,699.25 60,943.05 > Profit / ( loss ) before exceptional items and tax ( III - IV ) 5,983.99 3,733.60 5,478.46 18,698,65 VI Exceptional items ( gain ) ( Refer note 5 ) VII Profit / ( loss ) before tax ( V - VI ) VIII Tax expense : Current tax Deferred tax IX Profit / ( loss ) for the period ( VII - VIII ) " ( 279.90 ) ( 738.92 ) 5,983.99 3,733.60 5,758.36 19,437,57 1,050.89 38.95 689.29 ( 373.44 ) 1,012.33 121.28 3,436.18 ( 493.08 ) 4,894.15 3,417.75 4,624.75 16,494.47 × Other comprehensive income A ( i ) Items that will not be reclassified to profit or loss 25.65 16.27 5.51 32.33 ( ii ) Income tax relating to items that will not be reclassified to profit or loss ( 8.96 ) ( 1.87 ) ( 1.93 ) ( 7.49 ) B ( i ) Items that will be reclassified to profit or loss ( i ) Income tax relating to items that will be reclassified to profit or loss xx XI Total comprehensive income 4,910.84 3,432.15 4,628.33 16,519.31 XII Total comprehensive income attributable to : Non - controlling interests Owners of the Company XIII Other equity 4,910.84 3,432.15 4,628.33 16,519.31 1,47,812.89 XIV Earning per share ( EPS ) ( of Re 1 / - each ) ( not annualised ) * Basic EPS ( in Rupees ) 17.34 12.11 16.39 58.46 Diluted EPS ( in Rupees ) 17.34 12.11 16.39 58.46 * except for the year ended 31 March MUM GLEN PHAR MUMBAI ALS LTD ACEUTICA Glenmark Pharmaceuticals Ltd. Glenmark House , B D Sawant Marg , Andheri ( E ) , Mumbai - 400 099 , India T : 91 22 4018 9999 F : 91 22 4018 9986 CIN No : L24299MH1977PLC019982 W : www.glenmarkpharma.com Registered office : B / 2 , Mahalaxmi Chambers , 22 Bhulabhai Desai Road , Mumbai 400 026 E : complianceofficer@glenmarkpharma.com